2011 - BSS 2011 Symposium


Plenary Session 4: Chronic Rejection, Inflammation and Tissue Remodeling

8.1 - Organ Injury Determinates Transplant Outcome

Presenter: Yuan, Zhai, Los Angeles, United States
Authors: Yuan Zhai



Immune activation and regulation in liver ischemia reperfusion injury (IRI)
Zhai, Yuan

IRI is associated with multiple clinical settings and remains to be the major limiting factor in liver transplantation.  No effective and specific therapies are current available.  Since IR-triggered tissue inflammation is the major driving force of the development of full scale of IRI, we have been studying mechanisms of liver immune activation by IR.  By gene array analysis of ischemic liver tissues early after reperfusion, we have identified critical biological pathways associated with graft failure.  Among them, the TLR4-type I interferon and CXCL10 pathway plays an essential role in the activation of liver immune response against IR and may link the interaction of liver innate and adaptive immune systems.  Although liver IRI occurs in the absence of exogenous Ags, CD4 T cells are critically involved in liver tissue inflammation.  By dissecting the functional mechanism of CD4 T cells, we have demonstrated a new paradigm of adaptive T cell regulation of innate immune response by reverse signaling via CD154-CD40 pathway in an Ag-non-specific manner in liver IRI.  These studies shall provide us rationales to design novel therapeutic strategies to ameliorate liver IRI in clinical patients.


You must be logged in to view recordings

Important Disclaimer

By viewing the material on this site you understand and accept that:

  1. The opinions and statements expressed on this site reflect the views of the author or authors and do not necessarily reflect those of The Transplantation Society and/or its Sections.
  2. The hosting of material on The Transplantation Society site does not signify endorsement of this material by The Transplantation Society and/or its Sections.
  3. The material is solely for educational purposes for qualified health care professionals.
  4. The Transplantation Society and/or its Sections are not liable for any decision made or action taken based on the information contained in the material on this site.
  5. The information cannot be used as a substitute for professional care.
  6. The information does not represent a standard of care.
  7. No physician-patient relationship is being established.

Our Corporate Sponsors

TTS gratefully acknowledges the Corporate Partners whose generous support makes the work of the Society possible:

  • astellas
  • roche
  • sanofi